Lung Cancer Clinical Trial
Official title:
Analysis of P-selectin Expression on Platelets of Blood Between Serum Samples From Lung Cancer and Healthy Individuals by Using Raman Spectroscopy
Purpose:
Selectins are vascular cell adhesion molecules involved in adhesive interactions of
leukocytes and platelets and endothelium within the blood circulation.
Plasma soluble P selectin (sP-selectin), is a one of member of selectin family, an adhesion
molecule and component of the membrane of the platelet alpha granulate has been proposed as
a one marker of platelet activation. In this study we evaluate of expression of P selectin
on platelets of blood between serum samples from lung cancer and healthy individuals.
Material and Methods:
The investigators enrolled patients with lung cancer which divided on 3 group: 1- 23
patients with operating tumor; 2-ten patients with advanced and metastatic disease who
received palliative RT (RT - radiotherapy); 3-five patients with advanced inoperable
disease, who received radical RT or RT + CT (CT- chemotherapy).
In 1 group the specimens of blood we collected before surgery and 1-2 month after. In 2
group - before palliative treatment and in group 3 before radical treatment and one month
after completion treatment. To compare to serum specimens from patients with lung cancer was
obtained plasma from healthy volunteers.
Serum separation and Raman spectroscopy analysis:
A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.
The Raman spectra (RS) of the solid residues from serum samples were measurement by placing
10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least
30 min. The Raman system (Renishaw inVia Microscope integrated with Leica microscope) was
calibrated with a silicon standard using the Raman peak at 520 cm-1. Multiple scans were
conducted on the solid residue by moving the substrate on an X - Y stage. The wavelength of
excitation was 785 nm and the laser beam was focused on the surface of the sample with a 50x
objective. The radius on the beam was 3.0 µm and the laser power irradiation over the sample
was 5mW. Each spectrum was taken with an exposure of 30s, 10 accumulation and collected in
the region from 400 to 1540 cm-1.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|